Navigation Links
Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results
Date:11/9/2010

like_it .cf_socialicons.cf_clickable").live("mouseup", function (){ cf_jq(".cf_pushbutton_activate").live("mouseover", function (){ //Omniture Link Tracking Code /*var s=s_gi(s_account); s.linkTrackVars='eVar3,prop15,prop16'; s.linkTrackEvents='None'; s.eVar3=s.prop16; s.prop15='Test'; //Newsrelease id s.prop16='CrowdFactory_Share'; s.tl(this,'o', 'CrowdFactory_Share');*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='106970108';s.prop16='CrowdFactory_Share';s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_Share'); }); cf_jq(".cf_dialog_footer button").live("mouseup", function (){ var socialText = this.innerHTML.replace("Post to ", ""); /*s.linkTrackVars='eVar3,prop15,prop16'; s.linkTrackEvents='None'; s.prop16='CrowdFactory_'+socialText; s.eVar3=s.prop16; s.prop15='Test'; //Newsrelease id s.tl(this,'o', 'CrowdFactory_'+socialText);*/ var s=s_gi(s_account);s.linkTrackVars='prop5,eVar3,prop15,prop16,prop49,events';s.linkTrackEvents='event12';s.prop5='share it release';s.eVar3=s.prop5; s.prop15='106970108';s.prop16='CrowdFactory_'+socialText;s.prop5+='_'+s.prop16;s.prop49=s.pageName;s.events='event12';s.tl(this,'o','CrowdFactory_'+socialText); }); });  

QUEBEC CITY, Nov. 9 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS, TSX: AEZ) ("the Company") today reported financial and operating results for the third quarter ended September 30, 2010.

The Company's lead oncology compounds, perifosine, in Phase 3 registration trials for multiple myeloma and advanced colorectal cancer as well as in other earlier-stage cancer trials, and AEZS-108 in Phase 2 trials in advanced ovarian and endometrial cancer, continued to make significant progress.

"We are proud of the progress we have made over the last quarter as these products demonstrate our commitment to improving oncol
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
4. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
9. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
10. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Institute for Molecular Medicine Finland (FIMM), University of ... novel "man and machine" decision support system for ... described in PLOS One scientific journal ... computer vision algorithms similar to those used in ... the diagnostically most relevant areas. Tablet computers can ...
(Date:8/21/2014)... Aug. 21, 2014 Telomere Biosciences, LLC ... Nutraceutical "TELO-20 for Dogs" with Telomerase Activation ... in the world for dogs. Telomeres are the ... in the body. A wealth of ground-breaking research ... Telomere Science and Aging, including Nobel laureates, has ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... 2014 SoundConnect , a ... as one of the nation’s Fastest Growing Private ... the 2nd consecutive year. Inc. magazine today ranked ... 500|5000, an exclusive ranking of the nation's fastest-growing ... look at the most important segment of the ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
... BEDFORD, Mass., Sept. 2 VisEn Medical Inc., a leader ... today the commercial launch of its new Annexin-Vivo 750 imaging ... . The new Annexin-Vivo 750 agent is based on ... It is expected to significantly expand research areas and enhance drug development ...
... , , SAN DIEGO, Sept. 2 ... OPTR ) lead developmental product candidates will be ... and Chemotherapy (ICAAC) to be held at The Moscone Center in San ... http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) , , , ...
... , SILVER SPRING, Md., Sept. 1 United Therapeutics ... of Directors has approved and declared a stock split. The ... dividend, in which one share of United Therapeutics common stock will ... (or held in treasury) at the close of business on the ...
Cached Biology Technology:VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent 2VisEn Launches New Annexin-Vivo 750 Fluorescence Molecular Imaging Agent 3Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 2Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting 3United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend 2
(Date:8/21/2014)... Israel Deaconess Medical Center (BIDMC ) are among the ... Minds 2014," a comprehensive list compiled by ... science metrics and research performance analysis. , ... performing and publishing work that their peers recognized as ... a Thomson Reuters statement. Researchers were identified based on ...
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
(Date:8/21/2014)... tube connectors, designed by an international standards process, will ... According to an invited review published in the OnlineFirst ... NCP ), the official journal of the American Society ... will greatly reduce the occurrence of misconnection that can ... connectors, which are used to join medical devices, components, ...
Breaking Biology News(10 mins):BIDMC researchers named among 'the most influential scientific minds' 2BIDMC researchers named among 'the most influential scientific minds' 3Water window imaging opportunity 2New feeding tube connectors will improve patient safety 2
... Saturday 02 April 2011: Promising new viral hepatitis data ... entry inhibitors --a new mechanism of action for drugs ... new hepatitis B and hepatitis D treatments for many ... replication (e.g. nucleotide/side analogues), and can lead to the ...
... greenhouse industry is big business in the United ... agricultural sales. Most of the ornamental plants grown ... greenhouse operations. These operations are classified as "intensive ... expensive resources (labor, water, and fertilizers) to produce ...
... on England,s unused agricultural land could produce enough biomass ... industry or the environment, according to research led by ... The study, funded by the UK Energy Research Centre ... which looks at the potential of planting short rotation ...
Cached Biology News:Entry inhibitors show promise as drugs with new MOA for treatment of HBV and HDV infection 2Green industry knowledge center introduced 2Green industry knowledge center introduced 3Short rotation energy crops could help meet UK's renewable energy targets 2
... The Fujifilm Life Science FLA-7000 excels at ... CBB-stained gel documentation. It features four easy-to-access ... and a filter for Imaging Plates) for ... a customizable choice of four kinds of ...
... has been optimized for the analysis of ... software to quickly and accurately locate and ... an ELISA plate or each section of ... been customized to incorporate standard ELISA analysis ...
For microscopy...
... General description: Humidity wells in the ... maintain chamber humidity and probe hydration around ... seal eliminates the risk of waterbath contamination. ... constant temperature waterbaths or hybridisation ovens. Linkage: ...
Biology Products: